Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Breast Neoplasms 33Lymphoma 25Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Non-Hodgkin 12Leukemia 9Hodgkin Disease 9Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Multiple Myeloma 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Sarcoma 6Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Triple Negative Breast Neoplasms 5Neutropenia 5Lymphoma, B-Cell, Marginal Zone 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Prostatic Neoplasms 4Osteosarcoma 4Lung Neoplasms 4Waldenstrom Macroglobulinemia 3Testicular Neoplasms 3Sarcoma, Ewing 3Rhabdomyosarcoma 3Neuroblastoma 3Neoplasm Metastasis 3

Interventions

eltrombopag 9avatrombopag 6Platelet Transfusion 6romiplostim 4Tranexamic Acid 3Radiotherapy 3Cytarabine 3oprelvekin 2hetrombopag 2Tretinoin 2Peripheral Blood Stem Cell Transplantation 2Filgrastim 2Cyclophosphamide 2Carboplatin 2Busulfan 2Amplified Fragment Length Polymorphism Analysis 2sodium thiosulfate 1siltuximab 1raltitrexed 1pegfilgrastim 1ofatumumab 1niraparib 1leridistim 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1apixaban 1Vorinostat 1Vitamin B 12 1Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thrombocytopenia × pegfilgrastim × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡